Skip to main content

Table 3 Glucoregulatory factors, body composition and CVD risk markers

From: Time-restricted feeding improves blood glucose and insulin sensitivity in overweight patients with type 2 diabetes: a randomised controlled trial

 

TRF group

Control group

pa

Wk0

Wk12

Change

Wk0

Wk12

Change

HbA1c (%)

8.68 ± 1.21

7.14 ± 0.89

− 1.54% ± 0.19

8.34 ± 1.09

7.68 ± 0.98

− 0.66% ± 0.16

 < 0.001

FPG (mmol/L)

9.73 ± 1.38

8.26 ± 0.86

− 1.47 ± 0.25

9.54 ± 1.26

8.76 ± 1.02

− 0.78 ± 0.21

 < 0.001

Insulin (mIU/L)

8.83 ± 1.19

8.40 ± 0.92

− 0.43 ± 0.18

8.84 ± 1.17

8.83 ± 0.96

− 0.01 ± 0.02

0.03

HOMA-β

3.09 ± 0.64

3.82 ± 0.65

0.73 ± 0.21

3.16 ± 0.52

3.43 ± 0.66

0.27 ± 0.10

0.005

HOMA-IR

3.71 ± 0.68

3.20 ± 0.72

− 0.51 ± 0.08

3.65 ± 0.73

3.53 ± 0.83

− 0.12 ± 0.06

0.02

Body weight (kg)

75.06 ± 4.42

72.08 ± 3.98

− 2.98 ± 0.43

74.68 ± 4.35

73.85 ± 4.26

− 0.83 ± 0.32

 < 0.001

BMI (kg/m2)

26.42 ± 1.96

24.78 ± 1.43

− 1.64 ± 0.38

26.08 ± 2.14

25.66 ± 2.08

− 0.42 ± 0.24

 < 0.001

MES total

2.12 ± 0.76

1.46 ± 0.43

− 0.66 ± 0.17

2.04 ± 0.87

1.83 ± 0.54

− 0.21 ± 0.04

0.006

MES OHA

1.72 ± 0.89

1.39 ± 0.56

− 0.33 ± 0.27

1.74 ± 0.46

1.65 ± 0.44

− 0.09 ± 0.24

0.01

MES Insulin

1.97 ± 0.62

1.65 ± 0.52

− 0.32 ± 0.26

1.91 ± 0.33

1.80 ± 0.29

− 0.11 ± 0.24

0.02

SF-12

63.56 ± 8.18

69.48 ± 7.09

5.92 ± 1.38

62.78 ± 7.49

64.49 ± 8.87

1.71 ± 1.41

 < 0.001

TG (mmol/L)

2.59 ± 1.22

2.36 ± 1.18

− 0.23 ± 0.08

2.46 ± 1.18

2.33 ± 1.16

− 0.13 ± 0.06

0.03

TC (mmol/L)

5.56 ± 1.10

5.24 ± 1.05

− 0.32 ± 0.07

5.32 ± 1.10

5.17 ± 1.05

− 0.15 ± 0.06

0.01

LDL-c (mmol/L)

3.67 ± 1.24

3.25 ± 1.19

− 0.42 ± 0.13

3.57 ± 1.04

3.36 ± 0.88

− 0.21 ± 0.13

0.02

HDL-c (mmol/L)

1.24 ± 0.31

1.08 ± 0.29

− 0.16 ± 0.04

1.19 ± 0.34

1.04 ± 0.36

− 0.15 ± 0.05

0.33

  1. Data are the means ± SDs
  2. HbA1c, haemoglobin A1c; FPG, fasting plasma glucose; HOMA-β, homeostasis model of assessment-estimated β function; HOMA-IR, homeostasis model of assessment-estimated insulin resistance; BMI, body mass index; MES, medication effects score (MES = (actual drug dose/maximum drug dose) * drug mean adjustment factor); OHA, oral hypoglycaemic agents; TG, triglyceride; TC, total cholesterol; LDL-c; low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol
  3. aObtained from repeated measures ANOVA
Back to article page

Nutrition & Metabolism

ISSN: 1743-7075

Contact us